Further Characterization of Ocular Safety Profile of Commercially Available Preserved and Preservative-Free Triamcinolone Acetonide

Li, Yuli; Chen, Hao; Hou, Jiangping; Zhang, Yin; Li, Guoxing; Gu, Xin; Luo, Li; Shen, Huanjun; Qu, Jia; Cheng, Lingyun

doi:10.1097/iae.0b013e31821e1f7c

Cited by 13 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, pilot studies of intravitreal/subconjunctival injection of the commercial TA suspension (Transton®) have shown incidents of high intraocular pressure and cataracts. [35][36][37] In our results, we also observed that four of the eleven rats (∼36%) administrated with the TA suspension exhibited the high IOP after 5 days of injection and two of the eleven (∼18%) rats administrated with the 2.0 wt% TA suspension had cataracts. Interestingly, no such complications were observed after the administration of our TA hydrogel during the whole period of study.…”

Section: In Vivo Compatibility Testsupporting

confidence: 72%

Supramolecular nanofibers of triamcinolone acetonide for uveitis therapy

Yang

Shi

et al. 2014

Nanoscale

Self Cite

View full text Add to dashboard Cite

Supramolecular nanofibers of prodrugs hold advantages for drug release due to their high drug payload, sustained and constant drug release behavior, and stimuli responsiveness. In this study, we report on a supramolecular hydrogel mainly formed by a clinically used drug triamcinolone acetonide (TA). Such a hydrogel could only be prepared via an ester bond hydrolysis process from its prodrug of succinated triamcinolone acetonide (STA). The resulting hydrogel could constantly release TA in the in vitro release experiment. The TA hydrogel possessed an excellent transscleral penetration ability, as evaluated by the in vitro transscleral transport study. The developed TA hydrogel also exhibited a great ocular compatibility in rats, as indicated by the optical coherence tomography (OCT) images, HE observation, and glial fibrillary acidic protein (GFAP) and vimentin immuno-staining assays of the retinas. Our TA hydrogel showed a decreased efficacy to inhibit ocular inflammation in the rat's experiment autoimmune uveitis (EAU) model compared to the commercial TA suspension (Transton), but without causing complications such as high intraocular pressure and cataracts. These promising properties of the hydrogel indicated its great potential for the treatment of eye diseases.

show abstract

Section: In Vivo Compatibility Testsupporting

confidence: 72%

Supramolecular nanofibers of triamcinolone acetonide for uveitis therapy

Yang

Shi

et al. 2014

Nanoscale

Self Cite

View full text Add to dashboard Cite

show abstract

“…For suprachoroidal TA injection, only one eye of each animal was used and the fellow eye was left untouched for control purpose. Following suprachoroidal injection, the eyes were monitored by ocular tomometry, indirect ophthalmoscopy, fundus photography, electroretinography (ERG), and histology after sacrifice as previously reported [24].…”

Section: Safety Studymentioning

confidence: 99%

Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model

Chen

Liu

et al. 2015

Journal of Controlled Release

Self Cite

View full text Add to dashboard Cite

“…Preservative-free TA formulations have been developed and registered as medical devices for intended intravitreal use; however, controversial results have been obtained with regard to their safety profiles. 9 , 15 – 17 …”

Section: Introductionmentioning

confidence: 99%

Safety Profile of Lutein- Versus Triamcinolone Acetonide–Based Vitreous Staining

Lazzara

Conti

Ferrara

et al. 2023

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

Purpose To assess the safety profile of a new lutein-based vitreous dye (LB-VD) formulation compared with various triamcinolone acetonide (TA) formulations with and without subsequent exposure to perfluorodecalin (PFD) in vitro. Methods Human adult retinal pigment epithelial cells (ARPE-19) were treated with the following formulations: undiluted preserved TA (TA-BA), diluted preserved TA (D-TA-BA), preservative-free TA (TA-PF), and LB-VD. First, cell tolerability was evaluated with MTT, LDH, and ATPlite assays after 1, 5, and 30 minutes of exposure to each tested formulation. Then, cells were sequentially exposed to formulations and PFD. After 24 hours of exposure to PFD, cell tolerability was evaluated through MTT and ATPlite assays. Results Among the formulations tested, LB-VD showed the highest levels of cell viability, cell metabolism, and cell proliferation and induced the lowest release of LDH, whereas the TA-based formulations demonstrated a cytotoxic effect on ARPE-19 cells in vitro. After subsequent 24-hour exposure to PFD, a greater reduction of cell viability was noted for all the formulations; however, this reduction was not significant only for the combination LB-VD-PFD, which was the best tolerated condition. Conclusions LB-VD showed a better safety profile compared with all TA-based formulations, even when used in combination with PFD. Translational Relevance In surgical practice, LB-VD may be preferred to TA-based formulations for vitreous staining in the light of its more favorable safety profile.

show abstract

Further Characterization of Ocular Safety Profile of Commercially Available Preserved and Preservative-Free Triamcinolone Acetonide

Abstract: The equivalent triamcinolone acetonide doses to 0.1 mL (4 or 12 mg) intravitreal injection for human eye were found safe in guinea pig eyes. No significant difference was noted for 0.1 mL intravitreal injection between Kenalog-40 and Triesence.

Cited by 13 publications

References 33 publications

Supramolecular nanofibers of triamcinolone acetonide for uveitis therapy

Supramolecular nanofibers of triamcinolone acetonide for uveitis therapy

Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model

Safety Profile of Lutein- Versus Triamcinolone Acetonide–Based Vitreous Staining

Contact Info

Product

Resources

About